Immunosenescence and hurdles in the clinical management of older HIV-patients

References

• May MT, Gompels M, Delpech V, Porter K, Orkin C, Kegg S, Hay P, Johnson M, Palfreeman A, Gilson R, et al. Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. AIDS 2014; 28:1193-202; PMID:24556869; https://doi.org/10.1097/QAD.0000000000000243
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Diagnoses of HIV infection in the United States and dependent areas: HIV surveillance report. 2014. Available at http://www.cdc.gov/hiv/group/age/olderamericans/index.html
   Google Scholar
• Centro Operativo Aids. Notiziario ISS-COA volume 28, numero 9. 2015. Available at http://www.iss.it/binary/ccoa/cont/HIV_AIDS_DIC_2015.pdf
   Google Scholar
• Guaraldi G, Zona S, Brothers TD, Carli F, Stentarelli C, Dolci G, Santoro A, Beghetto B, Menozzi M, Mussini C, et al. Aging with HIV vs. HIV seroconversion at older age: a diverse population with distinct comorbidity profiles. PLoS One 2015; 10(4):e011853; https://doi.org/10.1371/journal.pone.0118531
   Web of Science ®Google Scholar
• Cao W, Jamieson BD, Hultin LE, Hultin PM, Effros RB, Detels R. Premature aging of T cells is associated with faster HIV-1 disease progression. J Acquir Immune Defic Syndr 2009; 50:137-147; PMID: 19131896; https://doi.org/10.1097/QAI.0b013e3181926c28
   PubMed Web of Science ®Google Scholar
• Allers K, Bösel D, Epple HJ, Karcher H, Schmidt W, Kunkel D, Geelhaar-Karsch A, Schinnerling K, Moos V, Schneider T. Effect of age on the CD4+ T-cell impairment in HIV-infected persons. J Acquir Immune Defic Syndr 2014; 66:7-15; PMID: 24378723; https://doi.org/10.1097/QAI.0000000000000097
   PubMed Web of Science ®Google Scholar
• Deeks SG. HIV infection, inflammation, immunosenescence and aging. Annu Rev Med 2011; 62:141-55; PMID: 21090961; https://doi.org/10.1146/annurev-med-042909-093756
   PubMed Web of Science ®Google Scholar
• Effros RB. Telomere/telomerase dynamics within the human immune system: effect of chronic infection and stress. Exp Gerontol 2011; 46(2–3):135-40; PMID: 20833238; https://doi.org/10.1016/j.exger.2010.08.027
   PubMed Web of Science ®Google Scholar
• Tchkonia T, Zhu Y, van Deursen J, Campisi J, Kirkland J. Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. J Clin Invest 2013; 123(3):966-72; PMID: 23454759; https://doi.org/10.1172/JCI64098
   PubMed Web of Science ®Google Scholar
• Zhu Y, L. Amstrong J, Tchkonia T, Kirkland J. Cellular senescence and the senescent secretory phenotype in age-related chronic diseases. Curr Opin Clin Metab Care 2014, 17:324-328; https://doi.org/10.1097/MCO.0000000000000065
   PubMed Web of Science ®Google Scholar
• Lujambio A. To clear, or not to clear (senescent cells)? That is the question Bioessays 2016; 38:S56-S64; PMID: 27417123; https://doi.org/10.1002/bies.201670910
   PubMed Web of Science ®Google Scholar
• Larsson LG. Oncogene-and tumor suppressor gene-mediated suppression of cellular senescence. Semin Cancer Biol 2011; 21:367-376; PMID: 22037160; https://doi.org/10.1016/j.semcancer.2011.10.005
   PubMed Web of Science ®Google Scholar
• OAR working group in HIV and Aging. HIV and aging: state of knowledge and areas of critical need for research. J Acquir Immune Defic Syndr 2012; 60:S1-18; PMID: 22688010; https://doi.org/10.1097/QAI.0b013e31825a3668
   PubMed Web of Science ®Google Scholar
• Pathai S, Bajillan H, Landay AL, High KP. Is HIV a model of accelerated or accentuated aging? J Gerontol A Biol Sci Med Sci 2014; 69(7):833-42; PMID: 24158766; https://doi.org/10.1093/gerona/glt168
   PubMed Web of Science ®Google Scholar
• Wikby A, Nilsson BO, Forsey R, Thompson J, Strindhall J, Löfgren S, Ernerudh J, Pawelec G, Ferguson F, Johansson B. The immune risk phenotype is associated with IL-6 in the terminal decline stage: findings from the Swedish NONA immune longitudinal study of very late life functioning. Mech Ageing Dev. 2006; 127(8):695-704; PMID: 16750842; https://doi.org/10.1016/j.mad.2006.04.003
   PubMed Web of Science ®Google Scholar
• Desai S, Landay A. Early immune senescence in HIV disease. Curr HIV/AIDS Rep 2010; 7:4-10; PMID: 20425052; https://doi.org/10.1007/s11904-009-0038-4
   PubMedGoogle Scholar
• Tenorio AR, Zheng Y, Bosch RJ, Krishnan S, Rodriguez B, Hunt PW, Plants J, Seth A, Wilson CC, Deeks SG, et al. Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. J Infect Dis 2014 15; 210(8):1248-59; PMID: 24795473; https://doi.org/10.1093/infdis/jiu254
   PubMed Web of Science ®Google Scholar
• Grund B, Baker JV, Deeks SG, Wolfson J, Wentworth D, Cozzi-Lepri A, Cohen CJ, Phillips A, Lundgren JD, Neaton JD, INSIGHT SMART/ESPRIT/SILCAAT Study Group. Relevance of interleukin-6 and D-dimer for serious non-AIDS morbidity and death among HIV-positive adults on suppressive antiretroviral therapy. PLoS One 2016; 11(5):e0155100; PMID: 27171281; https://doi.org/10.1371/journal.pone.0155100
   PubMed Web of Science ®Google Scholar
• Chiappetta S, Ripa M, Galli L, Razzari C, Longo V, Galli A, Faioni EM, Nozza S, Lazzarin A, Tambussi G. Soluble endothelial protein C receptor (sEPCR) as an inflammatory biomarker in naive HIV-infected patients during ART. J Antimicrob Chemother 2016; 71(6):1627-31; PMID: 26888911; https://doi.org/10.1093/jac/dkw010
   PubMed Web of Science ®Google Scholar
• Rodríguez-Mora S, Mateos E, Moran M, Má Martín, López JA, Calvo E, Terrón MC, Luque D, Muriaux D, Alcamí J, et al. Intracellular expression of Tat alters mitochondrial functions in T cells: a potential mechanism to understand mitochondrial damage during HIV-1 replication. Retrovirology 2015; 12:78; PMID: 26376973; https://doi.org/10.1186/s12977-015-0203-3
   PubMed Web of Science ®Google Scholar
• Strahl C, Blackburn EH. Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines. Mol. Cell Biol 1996; 16:53-65; PMID: 8524329; https://doi.org/10.1128/MCB.16.1.53
   PubMed Web of Science ®Google Scholar
• Caron M, Auclair M, Vigouroux C, Glorian M, Forest C, Capeau J. The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes. 2001; 50(6):1378-88; PMID: 11375339; https://doi.org/10.2337/diabetes.50.6.1378
   PubMed Web of Science ®Google Scholar
• Zha BS, Wan X, Zhang X, Zha W, Zhou J, Wabitsch M, Wang G, Lyall V, Hylemon PB, Zhou H. HIV protease inhibitors disrupt lipid metabolism by activating endoplasmic reticulum stress and inhibiting autophagy activity in adipocytes. PLoS One 2013; 8(3):e59514; PMID: 23533630; https://doi.org/10.1371/journal.pone.0059514
   PubMed Web of Science ®Google Scholar
• Gallego-Escuredo JM, Del Mar Gutierrez M, Diaz-Delfin J, Domingo JC, Mateo MG, Domingo P, Giralt M, Villarroya F. Differential effects of efavirenz and lopinavir/ritonavir on human adipocyte differentiation, gene expression and release of adipokines and pro-inflammatory cytokines. Curr HIV Res 2010; 8(7):545-53; PMID: 21073442; https://doi.org/10.2174/157016210793499222
   PubMed Web of Science ®Google Scholar
• Díaz-Delfín J, Domingo P, Giralt M, Villarroya F. Maraviroc reduces cytokine expression and secretion in human adipose cells without altering adipogenic differentiation. Cytokine 2013; 61(3):808-15; PMID: 23357304; https://doi.org/10.1016/j.cyto.2012.12.013
   PubMed Web of Science ®Google Scholar
• Effros RB, Fletcher CV, Gebo K, Halter JB, Hazzard WR, Horne FM, Huebner RE, Janoff EN, Justice AC, Kuritzkes D, et al. Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions. Clin. Infect. Dis 2008; 47:542-553; PMID: 18627268; https://doi.org/10.1086/590150
   PubMed Web of Science ®Google Scholar
• Söderberg-Nauclér C, Fornara O, Rahbar A. Cytomegalovirus driven immunosenescence-An immune phenotype with or without clinical impact? Mech Ageing Dev 2016
   PubMed Web of Science ®Google Scholar
• Effros RB. The silent war of CMV in aging and HIV infection. Mech Ageing Dev 2015 PMID: 26404009
   PubMed Web of Science ®Google Scholar
• Bandaranayake T, Shaw A. Host resistance and immune aging. Clin Geriatr Med 2016 32 415-432; PMID: 27394014; https://doi.org/10.1016/j.cger.2016.02.007
   PubMed Web of Science ®Google Scholar
• He S, Zhang Z, Fu Y, Qin C, Li S, Han X, Xu J, Liu J, Jiang Y, Shang H. Thymic function is most severely impaired in chronic HIV-1 infection, but individuals with faster disease progression during early HIV-1 infection expressed lower levels of RTEs. J Acquir Immune Defic Syndr 2015; 70(5):472-8; PMID: 26569175; https://doi.org/10.1097/QAI.0000000000000801
   PubMed Web of Science ®Google Scholar
• Kohler S, Thiel A. Life after the thymus: CD31+ and CD31-human naïve CD4+ T-cell subsets. Blood 2009; 113:769-774; PMID: 18583570; https://doi.org/10.1182/blood-2008-02-139154
   PubMed Web of Science ®Google Scholar
• den Braber I, Mugwagwa T, Vrisekoop N, Westera L, Mögling R, de Boer AB, Willems N, Schrijver EH, Spierenburg G, Gaiser K, et al. Maintenance of peripheral naive T cells is sustained by thymus output in mice but not humans. Immunity 2012; 36:288-297; PMID: 22365666; https://doi.org/10.1016/j.immuni.2012.02.006
   PubMed Web of Science ®Google Scholar
• Sauce D, Larsen M, Fastenackels S, Duperrier A, Keller M, Grubeck-Loebenstein B, Ferrand C, Debré P, Sidi D, Appay V. Evidence of premature immune aging in patients thymectomized during early childhood. J Clin Invest 2009; 119:3070-8; PMID: 19770514; https://doi.org/10.1172/JCI39269
   PubMed Web of Science ®Google Scholar
• Rickabaugh TM, Jamieson BD. A challenge for the future: aging and HIV infection. Immunol Res 2010; 48:59-71; PMID: 20734158; https://doi.org/10.1007/s12026-010-8167-9
   PubMed Web of Science ®Google Scholar
• Kohler S, Wagner U, Pierer M, Kimmig S, Oppmann B, Möwes B, Jülke K, Romagnani C, Thiel A. Post-thymic in vivo proliferation of naive CD4+ T cells constrains the TCR repertoire in healthy human adults. Eur J Immunol 2005; 35:1987-1994; PMID: 15909312; https://doi.org/10.1002/eji.200526181
   PubMed Web of Science ®Google Scholar
• Rickabaugh TM, Kilpatrick RD, Hultin LE, Hultin PM, Hausner MA, Sugar CA, Althoff KN, Margolick JB, Rinaldo CR, Detels R, et al. The dual impact of HIV-1 infection and aging on naïve CD4+ T-cells: additive and distinct patterns of impairment. Plos ONE 2011; 6(1):e16459; PMID: 21298072; https://doi.org/10.1371/journal.pone.0016459
   PubMed Web of Science ®Google Scholar
• Britanova OV, Putintseva EV, Shugay M, Merzlyak EM, Turchaninova MA, Staroverov DB, Bolotin DA, Lukyanov S, Bogdanova EA, Mamedov IZ, et al. Age-related decrease in TCR repertoire diversity measured with deep and normalized sequence profiling. J Immunol 2014; 192(6):2689-98; PMID: 24510963; https://doi.org/10.4049/jimmunol.1302064
   PubMed Web of Science ®Google Scholar
• Chou JP, Effros RB. T cell replicative senescence in human aging. Curr Pharm Des 2013; 19(9):1680-1698. PMID: 23061726
   PubMed Web of Science ®Google Scholar
• Fulop T, Le Page A, Fortin C, Witkowski JM, Dupuis G, Larbi A. Cellular signaling in the aging immune system. Current Opinion in Immunology 2014; 29:105-111; PMID: 24934647; https://doi.org/10.1016/j.coi.2014.05.007
   PubMed Web of Science ®Google Scholar
• Kovaiou RD, Weiskirchner I, Keller M, Pfister G, Cioca DP, Grubeck-Loebenstein B. Age-related differences in phenotype and function of CD4+ T cells are due to a phenotypic shift from naive to memory effector CD4+ T cells. Int Immunol 2005; 17(10):1359-66; PMID: 16141244; https://doi.org/10.1093/intimm/dxh314
   PubMed Web of Science ®Google Scholar
• Jackola DR, Ruger JK, Miller RA. Age-associated changes in human T cell phenotype and function. Aging (Milano) 1994; 6:25-34. PMID: 8043623
   PubMedGoogle Scholar
• Bisset LR, Lung TL, Kaelin M, Ludwig E, Dubs RW. Reference values for peripheral blood lymphocyte phenotypes applicable to the healthy adult population in Switzerland. Eur J Haematol 2004; 72:203-212; PMID: 14962239; https://doi.org/10.1046/j.0902-4441.2003.00199.x
   PubMed Web of Science ®Google Scholar
• Mandell Douglas, and Bennett's Principles and Practice of Infectious Diseases, 8th Edition
   Google Scholar
• Murray AJ, Kwon KJ, Farber DL, Siliciano RF. The latent reservoir for HIV-1: how immunologic memory and clonal expansion contribute to HIV-1 persistence. J Immunol 2016;197(2):407-17; PMID: 27382129; https://doi.org/10.4049/jimmunol.1600343
   PubMed Web of Science ®Google Scholar
• Appay V, Dunbar PR, Callan M, Klenerman P, Gillespie GM, Papagno L, Ogg GS, King A, Lechner F, Spina CA, et al. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med 2002; 8:379-385; PMID: 11927944; https://doi.org/10.1038/nm0402-379
   PubMed Web of Science ®Google Scholar
• Effros RB. Impact of the hayflick limit on T cell responses to infection: lessons from aging and HIV disease. Mech Ageing Dev 2004; 125:103-106; PMID: 15037010; https://doi.org/10.1016/j.mad.2003.11.003
   PubMed Web of Science ®Google Scholar
• Sainz T, Serrano-Villar S, Díaz L, González Tomé MI, Gurbindo MD, de José MI, Mellado MJ, Ramos JT, Zamora J, Moreno S, et al. The CD4/CD8 ratio as a marker T-cell activation, senescence and activation/exhaustion in treated HIV-infected children and young adults. AIDS 2013; 27(9):1513-6; PMID: 23435292; https://doi.org/10.1097/QAD.0b013e32835faa72
   PubMed Web of Science ®Google Scholar
• Sandler NG, Sereti I. Can early therapy reduce inflammation? Curr Opin HIV AIDS 2014; 9:72-79; PMID: 24247669; https://doi.org/10.1097/COH.0000000000000020
   PubMed Web of Science ®Google Scholar
• Stacy S, Krolick KA, Infante AJ, Kraig E. Immunological memory and late onset autoimmunity. Mech Ageing Dev 2002; 123(8):975-85; PMID: 12044946; https://doi.org/10.1016/S0047-6374(02)00035-0
   PubMed Web of Science ®Google Scholar
• Abudulai LN, Fernandez S, Corscadden K, Hunter M, Kirkham LA, Post JJ, French MA. Chronic HIV-1 infection induces B-Cell dysfunction that is incompletely resolved by long-term antiretroviral therapy. J Acquir Immune Defic Syndr 2016; 71(4):381-9; PMID: 26914910; https://doi.org/10.1097/QAI.0000000000000869
   PubMed Web of Science ®Google Scholar
• Hu Z, Luo Z, Wan Z, Wu H, Li W, Zhang T, Jiang W. HIV-associated memory B cell perturbations. Vaccine 2015; 33(22):2524-2529; PMID: 25887082; https://doi.org/10.1016/j.vaccine.2015.04.008
   PubMed Web of Science ®Google Scholar
• Pogliaghi M, Ripa M, Pensieroso S, Tolazzi M, Chiappetta S, Nozza S, Lazzarin A, Tambussi G, Scarlatti G. Beneficial effects of cART initiated during primary and chronic HIV-1 infection on immunoglobulin-expression of memory B-cell subsets. PLoS One 2015; 10(10):e0140435; PMID: 26474181; https://doi.org/10.1371/journal.pone.0140435
   PubMed Web of Science ®Google Scholar
• Hearps AC, Maisa A, Cheng WJ, Angelovich TA, Lichtfuss GF, Palmer CS, Landay AL, Jaworowski A, Crowe SM. HIV infection induces age-related changes to monocytes and innate immune activation in young men that persist despite combination antiretroviral therapy. AIDS 2012; 26:843-853; PMID: 22313961; https://doi.org/10.1097/QAD.0b013e328351f756
   PubMed Web of Science ®Google Scholar
• Hearps AC, Martin GE, Angelovich TA, Cheng WJ, Maisa A, Landay AL, Jaworowski A, Crowe SM. Aging is associated with chronic innate immune activation and dysregulation of monocyte phenotype and function. Aging Cell 2012; 11:867-875; PMID: 22708967; https://doi.org/10.1111/j.1474-9726.2012.00851.x
   PubMed Web of Science ®Google Scholar
• Seidler S, Zimmermann HW, Bartneck M, Trautwein C, Tacke F. Age-dependent alterations of monocyte subsets and monocyte-related chemokine pathways in healthy adults. BMC Immunol 2010; 11:30; PMID: 20565954; https://doi.org/10.1186/1471-2172-11-30
   PubMed Web of Science ®Google Scholar
• Nyugen J, Agrawal S, Gollapudi S, Gupta S. Impaired functions of peripheral blood monocyte subpopulations in aged humans. J Clin Immunol 2010; 30:806-813; PMID: 20703784; https://doi.org/10.1007/s10875-010-9448-8
   PubMed Web of Science ®Google Scholar
• van Duin D, Mohanty S, Thomas V, Ginter S, Montgomery RR, Fikrig E, Allore HG, Medzhitov R, Shaw AC. Age-associated defect in human TLR-1/2 function. J Immunol 2007; 178:970-975; PMID: 17202359; https://doi.org/10.4049/jimmunol.178.2.970
   PubMed Web of Science ®Google Scholar
• Chang JJ, Lacas A, Lindsay RJ, Doyle EH, Axten KL, Pereyra F, Rosenberg ES, Walker BD, Allen TM, Altfeld M. Differential regulation of toll-like receptor pathways in acute and chronic HIV-1 infection. AIDS 2012; 26:533-541; PMID: 22210629; https://doi.org/10.1097/QAD.0b013e32834f3167
   PubMed Web of Science ®Google Scholar
• Heggelund L, Müller F, Lien E, Yndestad A, Ueland T, Kristiansen KI, Espevik T, Aukrust P, Frøland SS. Increased expression of toll-like receptor 2 on monocytes in HIV infection: possible roles in inflammation and viral replication. Clin Infect Dis 2004; 39:264-269; PMID: 15307037; https://doi.org/10.1086/421780
   PubMed Web of Science ®Google Scholar
• Huang J, Yang Y, Al-Mozaini M, Burke PS, Beamon J, Carrington MF, Seiss K, Rychert J, Rosenberg ES, Lichterfeld M, et al. Dendritic cell dysfunction during primary HIV-1 infection. J Infect Dis 2011; 204(10):1557-62; PMID: 21969335; https://doi.org/10.1093/infdis/jir616
   PubMed Web of Science ®Google Scholar
• Zapata HJ, Shaw AC. Aging of the human innate immune system in HIV infection. Curr Opin Immunol 2014; 0:127-136; https://doi.org/10.1016/j.coi.2014.06.007
   Web of Science ®Google Scholar
• Pera A, Campos C, López N, Hassouneh F, Alonso C, Tarazona R, Solana R. Immunosenescence: implications for response to infection and vaccination in older people. Maturitas. 2015; 82(1):50-5 ; PMID: 26044074; https://doi.org/10.1016/j.maturitas.2015.05.004
   PubMed Web of Science ®Google Scholar
• Scully E, Alter G. NK cells in HIV disease. Curr HIV/AIDS Rep. 2016; 13(2):85-94; PMID: 27002078; https://doi.org/10.1007/s11904-016-0310-3
   PubMed Web of Science ®Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf
   Google Scholar
• WHO. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV 30 September 2015. Available at http://www.who.int/hiv/pub/guidelines/earlyrelease-arv/en/
   Google Scholar
• WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. June 2016. Available at http://www.who.int/hiv/pub/arv/arv-2016/en/
   Google Scholar
• European AIDS Clinical Society. EACS Guidelines 8.0. Available at http://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html
   Google Scholar
• BHIVA guidelines for the treatment of HIV-1-positive adults with ART 2015 (2016 interim update). Available at http://www.bhiva.org/HIV-1-treatment-guidelines.aspx
   Google Scholar
• Edwards JK, Cole SR, Westreich D, Mugavero MJ, Eron JJ, Moore RD, Mathews WC, Hunt P, Williams C, Centers for AIDS Research Network of Integrated Clinical Systems investigators. Age at entry into care, timing of antiretroviral therapy initiation, and 10-year mortality among HIV-seropositive adults in the United States. Clin Infect Dis 2015; 61(7):1189-95; PMID: 26082505; https://doi.org/10.1093/cid/civ463
   PubMed Web of Science ®Google Scholar
• Smit M, Brinkman K, Geerlings S, Smit C, Thyagarajan K, Sighem Av, de Wolf F, Hallett TB, ATHENA observational cohort. Future challenges for clinical care of an ageing population infected with HIV: a modelling study. Lancet Infect Dis 2015; 15(7):810-8; PMID: 26070969; https://doi.org/10.1016/S1473-3099(15)00056-0
   PubMed Web of Science ®Google Scholar
• Allavena C, Bernaud C, Lariven S, Valantin M, Ferry T, Cuzin L, Naqvi A, Hanf M, Cabié A, for the DatAIDS study group. Ageing with HIV: emerging importance of chronic comorbidities in patients over 75. Conference on Retroviruses and Opportunistic Infections (CROI), February 22–25, 2016, Boston. Abstract 709
   Google Scholar
• Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group, Sabin CA, Smith CJ, d'Arminio Monforte A, Battegay M, Gabiano C, Galli L, Geelen S, Gibb D, Guiguet M, et al. Response to combination antiretroviral therapy: variation by age. AIDS 2008; 22(12):1463-73; PMID: 18614870; https://doi.org/10.1097/QAD.0b013e3282f88d02
   PubMed Web of Science ®Google Scholar
• Ewings FM, Bhaskaran K, McLean K, Hawkins D, Fisher M, Fidler S, Gilson R, Nock D, Brettle R, Johnson M, et al. Survival following HIV infection of a cohort followed up from seroconversion in the UK. AIDS 2008; 22(1):89-95; PMID: 18090396; https://doi.org/10.1097/QAD.0b013e3282f3915e
   PubMed Web of Science ®Google Scholar
• May M, Sterne JA, Sabin C, Costagliola D, Justice AC, Thiébaut R, Gill J, Phillips A, Reiss P, Hogg R, Ledergerber B, et al. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS 2007; 21(9):1185-97; PMID: 17502729; https://doi.org/10.1097/QAD.0b013e328133f285
   PubMed Web of Science ®Google Scholar
• Mussini C, Manzardo C, Johnson M, Ad Monforte, Uberti-Foppa C, Antinori A, Gill MJ, Sighinolfi L, Borghi V, Lazzarin A, et al. Patients presenting with AIDS in the HAART era: a collaborative cohort analysis. AIDS 2008; 22(18):2461-9; PMID: 19005269; https://doi.org/10.1097/QAD.0b013e328314b5f1
   PubMed Web of Science ®Google Scholar
• Greenbaum AH, Wilson LE, Keruly JC, Moore RD, Gebo KA. Effect of age and HAART regimen on clinical response in an urban cohort of HIV-infected individuals. AIDS 2008; 22(17):2331-9; PMID: 18981772; https://doi.org/10.1097/QAD.0b013e32831883f9
   PubMed Web of Science ®Google Scholar
• O'Brien D, Spelman T, Greig J, McMahon J, Ssonko C, Casas E, Mesic A, Du Cros P, Ford N. Risk factors for mortality during antiretroviral therapy in older populations in resource-limited settings. J Int AIDS Soc 2016; 19(1):20665; PMID: 26782169; https://doi.org/10.7448/IAS.19.1.20665
   PubMed Web of Science ®Google Scholar
• Silverberg MJ, Leyden W, Horberg MA, DeLorenze GN, Klein D, Quesenberry CP Jr. Older age and the response to and tolerability of antiretroviral therapy. Arch Intern Med 2007; 167(7):684-91; PMID: 17420427; https://doi.org/10.1001/archinte.167.7.684
   PubMed Web of Science ®Google Scholar
• Grabar S, Kousignian I, Sobel A, Le Bras P, Gasnault J, Enel P, Jung C, Mahamat A, Lang JM, Costagliola D. Immunologic and clinical responses to highly active antiretroviral therapy over 50 years of age. Results from the French Hospital Database on HIV. AIDS 2004; 18(15):2029-38
   Google Scholar
• Porter K, Walker S, Hill T, Anderson J, Leen C, Johnson M, Gazzard B, Walsh J, Fisher M, Orkin C, et al. Changes in outcome of persons initiating highly active antiretroviral therapy at a CD4 count less than 50 Cells/mm3. J Acquir Immune Defic Syndr 2008; 47(2):202-5; PMID: 17971709; https://doi.org/10.1097/QAI.0b013e31815b1291
   PubMed Web of Science ®Google Scholar
• Mussini C, Manzardo C, Johnson M, Ad Monforte, Uberti-Foppa C, Antinori A, Gill MJ, Sighinolfi L, Borghi V, et al. Patients presenting with AIDS in the HAART era: a collaborative cohort analysis. AIDS 2008; 22(18):2461-9; PMID: 19005269; https://doi.org/10.1097/QAD.0b013e328314b5f1
   PubMed Web of Science ®Google Scholar
• Lampe FC, Gatell JM, Staszewski S, Johnson MA, Pradier C, Gill MJ, de Lazzari E, Dauer B, Youle M, Fontas E, Krentz HB, Phillips AN. Changes over time in risk of initial virological failure of combination antiretroviral therapy: a multicohort analysis, 1996 to 2002. Arch Intern Med 2006; 166(5):521-8.
   Google Scholar
• Hall HI, Frazier EL, Rhodes P, Holtgrave DR, Furlow-Parmley C, Tang T, Gray KM, Cohen SM, Mermin J, Skarbinski J. Differences in human immunodeficiency virus care and treatment among subpopulations in the United States. JAMA Intern Med 2013; 173(14):1337-44; PMID: 23780395; https://doi.org/10.1001/jamainternmed.2013.6841
   PubMed Web of Science ®Google Scholar
• Ghidei L, Simone MJ, Salow MJ, Zimmerman KM, Paquin AM, Skarf LM, Kostas TR, Rudolph JL. Aging, antiretrovirals, and adherence: a meta analysis of adherence among older HIV-infected individuals. Drugs Aging 2013; 30(10):809-19; PMID: 23959913; https://doi.org/10.1007/s40266-013-0107-7
   PubMed Web of Science ®Google Scholar
• Hinkin CH, Hardy DJ, Mason KI, Castellon SA, Durvasula RS, Lam MN, Stefaniak M. Medication adherence in HIV-infected adults: effect of patient age, cognitive status, and substance abuse. AIDS 2004; 18 Suppl 1:S19-25; PMID: 15075494; https://doi.org/10.1097/00002030-200418001-00004
   PubMed Web of Science ®Google Scholar
• Krentz HB, Gill MJ. The impact of non-antiretroviral polypharmacy on the continuity of antiretroviral therapy (ART) among HIV patients. AIDS Patient Care STDS 2016; 30(1):11-7; PMID: 26544766; https://doi.org/10.1089/apc.2015.0199
   PubMed Web of Science ®Google Scholar
• Abara WE, Adekeye OA, Xu J, Heiman HJ, Rust G. Correlates of combination antiretroviral adherence among recently diagnosed older HIV-infected adults between 50 and 64 years. AIDS Behav 2016; 20(11):2674-81; PMID: 26885812
   PubMed Web of Science ®Google Scholar
• Engsig FN, Zangerle R, Katsarou O, Dabis F, Reiss P, Gill J, Porter K, Sabin C, Riordan A, Fätkenheuer G, et al. Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery. Clin Infect Dis 2014; 58(9):1312-21; PMID: 24457342; https://doi.org/10.1093/cid/ciu038
   PubMed Web of Science ®Google Scholar
• Goetz MB, Boscardin WJ, Wiley D, Alkasspooles S. Decreased recovery of CD4 lymphocytes in older HIV-infected patients beginning highly active antiretroviral therapy. AIDS 2001; 15(12):1576-9; PMID: 11504992; https://doi.org/10.1097/00002030-200108170-00017
   PubMed Web of Science ®Google Scholar
• Kaufmann GR, Furrer H, Ledergerber B, Perrin L, Opravil M, Vernazza P, Cavassini M, Bernasconi E, Rickenbach M, Hirschel B, et al. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin Infect Dis 2005; 41(3):361-72; PMID: 16007534; https://doi.org/10.1086/431484
   PubMed Web of Science ®Google Scholar
• Florence E, Lundgren J, Dreezen C, Fisher M, Kirk O, Blaxhult A, Panos G, Katlama C, Vella S, Phillips A, EuroSIDA Study Group. Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study. HIV Med 2003; 4(3):255-62; PMID: 12859325; https://doi.org/10.1046/j.1468-1293.2003.00156.x
   PubMedGoogle Scholar
• Baker JV, Peng G, Rapkin J, Krason D, Reilly C, Cavert WP, Abrams DI, MacArthur RD, Henry K, Neaton JD. Poor initial CD4+ recovery with antiretroviral therapy prolongs immune depletion and increases risk for AIDS and non-AIDS diseases. J Acquir Immune Defic Syndr 2008; 48(5):541-6; PMID: 18645520; https://doi.org/10.1097/QAI.0b013e31817bebb3
   PubMed Web of Science ®Google Scholar
• Hunt PW, Deeks SG, Rodriguez B, Valdez H, Shade SB, Abrams DI, Kitahata MM, Krone M, Neilands TB, Brand RJ, et al. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS 2003; 17(13):1907-15; PMID: 12960823; https://doi.org/10.1097/00002030-200309050-00009
   PubMed Web of Science ®Google Scholar
• Li X, Margolick JB, Jamieson BD, Rinaldo CR, Phair JP, Jacobson LP. CD4+ T-cell counts and plasma HIV-1 RNA levels beyond 5 years of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2011; 57(5):421-8; PMID: 21602699; https://doi.org/10.1097/QAI.0b013e31821e9f21
   PubMed Web of Science ®Google Scholar
• Althoff KN, Justice AC, Gange SJ, Deeks SG, Saag MS, Silverberg MJ, Gill MJ, Lau B, Napravnik S, Tedaldi E, et al. Virologic and immunologic response to HAART, by age and regimen class. AIDS 2010; 24(16):2469-79; PMID: 20829678; https://doi.org/10.1097/QAD.0b013e32833e6d14
   PubMed Web of Science ®Google Scholar
• Weber R, Sabin CA, Friis-Møller N, Reiss P, El-Sadr WM, Kirk O, Dabis F, Law MG, Pradier C, De Wit S, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166(15):1632-41; PMID: 16908797; https://doi.org/10.1001/archinte.166.15.1632
   PubMed Web of Science ®Google Scholar
• Study Group on Death Rates at High CD4 Count in Antiretroviral Naive Patients, Lodwick RK, Sabin CA, Porter K, Ledergerber B, van Sighem A, Cozzi-Lepri A, Khaykin P, Mocroft A, Jacobson L, et al. Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study. Lancet 2010; 376(9738):340-5; PMID: 20638118; https://doi.org/10.1016/S0140-6736(10)60932-4
   PubMed Web of Science ®Google Scholar
• Phillips AN, Neaton J, Lundgren JD. The role of HIV in serious diseases other than AIDS. AIDS 2008; 22(18):2409-18. https://doi.org/10.1097/QAD.0b013e3283174636; PMID: 19005264; https://doi.org/10.1097/QAD.0b013e3283174636
   PubMed Web of Science ®Google Scholar
• Goulet JL, Fultz SL, Rimland D, Butt A, Gibert C, Rodriguez-Barradas M, Bryant K, Justice AC. Aging and infectious diseases: do patterns of comorbidity vary by HIV status, age, and HIV severity? Clin Infect Dis 2007; 45(12):1593-601; PMID: 18190322; https://doi.org/10.1086/523577
   PubMed Web of Science ®Google Scholar
• Monforte Ad, Abrams D, Pradier C, Weber R, Reiss P, Bonnet F, Kirk O, Law M, De Wit S, Friis-Møller N, Phillips AN, Sabin CA, Lundgren JD, Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS 2008; 22(16):2143-53; PMID: 18832878; https://doi.org/10.1097/QAD.0b013e3283112b77
   PubMed Web of Science ®Google Scholar
• Triant VA, Regan S, Lee H, Sax PE, Meigs JB, Grinspoon SK. Association of immunologic and virologic factors with myocardial infarction rates in a US healthcare system. J Acquir Immune Defic Syndr 2010; 55(5):615-9; PMID: 20827215; https://doi.org/10.1097/QAI.0b013e3181f4b752
   PubMed Web of Science ®Google Scholar
• Lichtenstein KA, Armon C, Buchacz K, Chmiel JS, Buckner K, Tedaldi EM, Wood K, Holmberg SD, Brooks JT, HIV Outpatient Study (HOPS) Investigators. Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study. Clin Infect Dis 2010; 51(4):435-47; PMID: 20597691; https://doi.org/10.1086/655144
   PubMed Web of Science ®Google Scholar
• Data Collection on Adverse Events of Anti-HIV drugs (D:A:D) Study Group, Smith C, Sabin CA, Lundgren JD, Thiebaut R, Weber R, Law M, Monforte Ad, Kirk O, Friis-Moller N, et al. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D study. AIDS 2010; 24(10):1537-48. PMID: 20453631
   PubMed Web of Science ®Google Scholar
• Castilho JL, Shepherd BE, Koethe J, Turner M, Bebawy S, Logan J, Rogers WB, Raffanti S, Sterling TR. CD4+/CD8+ ratio, age, and risk of serious noncommunicable diseases in HIV-infected adults on antiretroviral therapy. AIDS 2016; 30(6):899-908; PMID: 26959354; https://doi.org/10.1097/QAD.0000000000001005
   PubMed Web of Science ®Google Scholar
• Shepherd L, Borges Á, Ledergerber B, Domingo P, Castagna A, Rockstroh J, Knysz B, Tomazic J, Karpov I, Kirk O, Lundgren J, Mocroft A, EuroSIDA in EuroCOORD. Infection-related and -unrelated malignancies, HIV and the aging population. HIV Med 2016; 17(8): 590-600; PMID: 26890156
   PubMed Web of Science ®Google Scholar
• Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord, Young J, Psichogiou M, Meyer L, Ayayi S, Grabar S, Raffi F, Reiss P, Gazzard B, Sharland M, et al. CD4 cell count and the risk of AIDS or death in HIV-Infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE. PLoS Med 2012; 9(3):e1001194; PMID: 22448150; https://doi.org/10.1371/journal.pmed.1001194
   PubMed Web of Science ®Google Scholar
• Zoufaly A, Cozzi-Lepri A, Reekie J, Kirk O, Lundgren J, Reiss P, Jevtovic D, Machala L, Zangerle R, Mocroft A, et al. Immuno-virological discordance and the risk of non-AIDS and AIDS events in a large observational cohort of HIV-patients in Europe. PLoS One 2014; 9(1):e87160; PMID: 24498036; https://doi.org/10.1371/journal.pone.0087160
   PubMed Web of Science ®Google Scholar
• Lapadula G, Chatenoud L, Gori A, Castelli F, Di Giambenedetto S, Fabbiani M, Maggiolo F, Focà E, Ladisa N, Sighinolfi L, et al. Risk of severe non AIDS events is increased among patients unable to increase their CD4+ T-cell counts >200+/μl despite effective HAART. PLoS One 2015; 10(5):e0124741; PMID: 26020949; https://doi.org/10.1371/journal.pone.0124741
   PubMed Web of Science ®Google Scholar
• Kasahara TM, Hygino J, Andrade RM, Monteiro C, Sacramento PM, Andrade AF, Bento CA. Poor functional immune recovery in aged HIV-1-infected patients following successfully treatment with antiretroviral therapy. Hum Immunol 2015; 76(10):701-10; PMID: 26429325; https://doi.org/10.1016/j.humimm.2015.09.023
   PubMed Web of Science ®Google Scholar
• Kalayjian RC, Spritzler J, Matining RM, Fiscus SA, Gross BH, Francis IR, Pollard RB, Lederman MM, Landay A. Older HIV-infected patients on antiretroviral therapy have B-cell expansion and attenuated CD4 cell increases with immune activation reduction. AIDS 2013; 27(10):1563-71; PMID: 24047762; https://doi.org/10.1097/QAD.0b013e32835fabc2
   PubMed Web of Science ®Google Scholar
• Asher I, Guri KM, Elbirt D, Bezalel SR, Maldarelli F, Mor O, Grossman Z, Sthoeger ZM. Characteristics and outcome of patients diagnosed with HIV at older age. Medicine (Baltimore) 2016; 95(1):e2327; PMID: 26735534; https://doi.org/10.1097/MD.0000000000002327
   PubMed Web of Science ®Google Scholar
• INSIGHT START Study Group, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, Avihingsanon A, Cooper DA, Fätkenheuer G, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med 2015; 373(9):795-807; PMID: 26192873; https://doi.org/10.1056/NEJMoa1506816
   PubMed Web of Science ®Google Scholar
• May MT, Gompels M, Delpech V, Porter K, Orkin C, Kegg S, Hay P, Johnson M, Palfreeman A, Gilson R, et al. Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. AIDS 2014; 28(8):1193-202; PMID: 24556869; https://doi.org/10.1097/QAD.0000000000000243
   PubMed Web of Science ®Google Scholar
• Marcus JL, Chao CR, Leyden WA, Xu L, Quesenberry CP Jr, Klein DB, Towner WJ, Horberg MA, Silverberg MJ. Narrowing the gap in life expectancy between HIV-infected and HIV-uninfected individuals with access to care. J Acquir Immune Defic Syndr 2016; 73(1):39-46.
   Web of Science ®Google Scholar
• Legarth RA, Ahlström MG, Kronborg G, Larsen CS, Pedersen C, Pedersen G, Mohey R, Gerstoft J, Obel N. Long-term mortality in HIV-infected individuals 50 years or older: a nationwide, population-based cohort study. J Acquir Immune Defic Syndr 2016; 71(2):213-8; PMID: 26334734; https://doi.org/10.1097/QAI.0000000000000825
   PubMed Web of Science ®Google Scholar
• Siddiqi AE, Hall HI, Hu X, Song R. Population-Based Estimates of Life Expectancy After HIV Diagnosis. United States 2008 – 2011. J Acquir Immune Defic Syndr. 2016
   Web of Science ®Google Scholar
• Patterson S, Cescon A, Samji H, Chan K, Zhang W, Raboud J, Burchell AN, Cooper C, Klein MB, Rourke SB, Loutfy MR, Machouf N, Montaner JS, Tsoukas C, Hogg RS, CANOC collaboration. Life expectancy of HIV-positive individuals on combination antiretroviral therapy in Canada. BMC Infect Dis 2015; 15:274; PMID: 26183704; https://doi.org/10.1186/s12879-015-0969-x
   PubMed Web of Science ®Google Scholar
• Nsanzimana S, Remera E, Kanters S, Chan K, Forrest JI, Ford N, Condo J, Binagwaho A, Mills EJ. Life expectancy among HIV-positive patients in Rwanda: a retrospective observational cohort study. Lancet Glob Health 2015; 3(3):e169-77; PMID: 25701995; https://doi.org/10.1016/S2214-109X(14)70364-X
   PubMed Web of Science ®Google Scholar
• Helleberg M, May MT, Ingle SM, Dabis F, Reiss P, Fätkenheuer G, Costagliola D, d'Arminio A, Cavassini M, Smith C, et al. Smoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America. AIDS 2015; 29(2):221-9; PMID: 25426809; https://doi.org/10.1097/QAD.0000000000000540
   PubMed Web of Science ®Google Scholar
• Gimeno-Gracia M, Crusells-Canales MJ, Javier Armesto-Gómez F, Rabanaque-Hernández MJ. Prevalence of concomitant medications in older HIV+ patients and comparison with general population. HIV Clin Trials 2015; 16(3):117-24; PMID: 25978302; https://doi.org/10.1179/1528433614Z.0000000012
   PubMed Web of Science ®Google Scholar
• Moore HN, Mao L, Oramasionwu CU. Factors associated with polypharmacy and the prescription of multiple medications among persons living with HIV (PLWH) compared to non-PLWH. AIDS Care 2015; 27(12):1443-8; PMID: 26608408; https://doi.org/10.1080/09540121.2015.1109583
   PubMed Web of Science ®Google Scholar
• Patel R, Moore T, Cooper V, McArdle C, Perry N, Cheek E, Gainsborough N, Fisher M. An observational study of comorbidity and healthcare utilisation among HIV-positive patients aged 50 years and over. Int J STD AIDS; 27(8):628-37; 0956462415589524
   Web of Science ®Google Scholar
• Marzolini C, Back D, Weber R, Furrer H, Cavassini M, Calmy A, Vernazza P, Bernasconi E, Khoo S, Battegay M, et al. Ageing with HIV: medication use and risk for potential drug-drug interactions. J Antimicrob Chemother 2011; 66(9):2107-11; PMID: 21680580; https://doi.org/10.1093/jac/dkr248
   PubMed Web of Science ®Google Scholar
• Nou E, Lo J, Hadigan C, Grinspoon SK. Pathophysiology and management of cardiovascular disease in patients with HIV. Lancet Diabetes Endocrinol 2016; 4(7):598-610; pii: S2213-8587(15)00388-5. PMID: 26873066
   PubMed Web of Science ®Google Scholar
• Schoen JC, Erlandson KM, Anderson PL. Clinical pharmacokinetics of antiretroviral drugs in older persons. Expert Opin Drug Metab Toxicol. 2013; 9(5):573-88; PMID: 23514375; https://doi.org/10.1517/17425255.2013.781153
   PubMed Web of Science ®Google Scholar
• Harb GE, Alldredge BK, Coleman R, Jacobson MA. Pharmacoepidemiology of adverse drug reactions in hospitalized patients with human immunodeficiency virus disease. J Acquir Immune Defic Syndr 1993; 6:919-26 PMID: 8315576
   PubMed Web of Science ®Google Scholar
• Mehta U, Durrheim DN, Blockman M, Kredo T, Gounden R, Barnes KI. Adverse drug reactions in adult medical inpatients in a South African hospital serving a community with a high HIV/AIDS prevalence: prospective observational study. Br J Clin Pharmacol 2008; 65(3):396-406; PMID: 18070223; https://doi.org/10.1111/j.1365-2125.2007.03034.x
   PubMed Web of Science ®Google Scholar
• Masenyetse LJ, Manda SO, Mwambi HG. An assessment of adverse drug reactions among HIV positive patients receiving antiretroviral treatment in South Africa. AIDS Res Ther 2015; 12:6; PMID: 25745501; https://doi.org/10.1186/s12981-015-0044-0
   PubMed Web of Science ®Google Scholar
• Sabin CA, Smith CJ, Delpech V, Anderson J, Bansi L, Gilson R, Schwenk A, Leen C, Gazzard B, Porter K, et al. The associations between age and the development of laboratory abnormalities and treatment discontinuation for reasons other than virological failure in the first year of highly active antiretroviral therapy. HIV Med 2009; 10(1):35-43; PMID: 19018876; https://doi.org/10.1111/j.1468-1293.2008.00654.x
   PubMed Web of Science ®Google Scholar
• Lodwick RK, Smith CJ, Youle M, Lampe FC, Tyrer M, Bhagani S, Chaloner C, Sabin CA, Johnson MA, Phillips AN. Stability of antiretroviral regimens in patients with viral suppression. AIDS 2008; 22(9):1039-46; PMID: 18520347; https://doi.org/10.1097/QAD.0b013e3282fec415
   PubMed Web of Science ®Google Scholar
• Prosperi MC, Fabbiani M, Fanti I, Zaccarelli M, Colafigli M, Mondi A, et al. Predictors of first-line antiretroviral therapy discontinuation due to drug- related adverse events in HIV-infected patients: a retrospective cohort study. BMC Infect Dis 2012; 12:296; PMID: 23145925; https://doi.org/10.1186/1471-2334-12-296
   PubMed Web of Science ®Google Scholar
• Orlando G, Meraviglia P, Valsecchi L, Mainini A, Schiavini M, Merli S, et al. cART durability and causes for treatment switching or discontinuation in HIV-positive patients older than 50 years of age. J Acquir Immune Defic Syndr 2010; 55(2):e12-4; PMID: 20859084; https://doi.org/10.1097/QAI.0b013e3181ef791b
   PubMed Web of Science ®Google Scholar
• Antela A, Aguiar C, Compston J, Hendry BM, Boffito M, Mallon P, Pourcher-Martinez V, Di Perri G. The role of tenofovir alafenamide in future HIV management. HIV Med 2016; 17 Suppl 2:4-16; PMID: 26952360; https://doi.org/10.1111/hiv.12401
   PubMed Web of Science ®Google Scholar
• Margolis DA, Brinson CC, Smith GH, de Vente J, Hagins DP, Eron JJ, Griffith SK, St Clair MH, Stevens MC, Williams PE, Ford SL, Stancil BS, Bomar MM, Hudson KJ, Smith KY, Spreen WR, LAI116482 Study Team. Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial. Lancet Infect Dis 2015; 15(10):1145-55; PMID: 26201299; https://doi.org/10.1016/S1473-3099(15)00152-8
   PubMed Web of Science ®Google Scholar
• Figueroa MI, Sued O, Patterson Gun A, Rolón MJ, Cahn P. Dolutegravir-lamivudine as initial therapy in HIV-infected ARV-naive patients: first results of the PADDLE trial. Program and abstracts of the 15th European AIDS Conference; October 21–24, 2015; Barcelona, Spain. Abstract 1066
   Google Scholar
• Babafemi T. Dolutegravir antiretroviral strategy to promote improvement and reduce drug exposure (ASPIRE). 2014. Available at: https://clinicaltrials.gov/ct2/show/NCT02263326
   Google Scholar
• Klatzmann D, Abbas AK. The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. Nat Rev Immunol 2015; 15(5):283-94; PMID: 25882245; https://doi.org/10.1038/nri3823
   PubMed Web of Science ®Google Scholar
• Lane HC, Fauci AS. Immunologic abnormalities in the acquired immunodeficiency syndrome. Annu Rev Immunol 1985; 3:477-500; PMID: 2415141; https://doi.org/10.1146/annurev.iy.03.040185.002401
   PubMed Web of Science ®Google Scholar
• INSIGHT-ESPRIT Study Group; SILCAAT Scientific Committee, Abrams D, Lévy Y, Losso MH, Babiker A, Collins G, Cooper DA, Darbyshire J, Emery S, et al. Interleukin-2 therapy in patients with HIV infection. N Engl J Med 2009; 361(16):1548-59; PMID: 19828532; https://doi.org/10.1056/NEJMoa0903175
   PubMed Web of Science ®Google Scholar
• Kovacs JA, Vogel S, Metcalf JA, Baseler M, Stevens R, Adelsberger J, Lempicki R, Hengel RL, Sereti I, Lambert L, et al. Interleukin-2 induced immune effects in human immunodeficiency virus-infected patients receiving intermittent interleukin-2 immunotherapy. Eur J Immunol 2001; 31(5):1351-60; PMID: 11465092; https://doi.org/10.1002/1521-4141(200105)31:5%3c1351::AID-IMMU1351%3e3.0.CO;2-9
   PubMed Web of Science ®Google Scholar
• Sereti I, Anthony KB, Martinez-Wilson H, Lempicki R, Adelsberger J, Metcalf JA, Hallahan CW, Follmann D, Davey RT, Kovacs JA, et al. IL-2-induced CD4+ T-cell expansion in HIV-infected patients is associated with long-term decreases in T-cell proliferation. Blood 2004; 104(3):775-80; PMID: 15090457; https://doi.org/10.1182/blood-2003-12-4355
   PubMed Web of Science ®Google Scholar
• Sereti I, Imamichi H, Natarajan V, Imamichi T, Ramchandani MS, Badralmaa Y, Berg SC, Metcalf JA, Hahn BK, Shen JM, et al. In vivo expansion of CD4CD45RO-CD25 T cells expressing foxP3 in IL-2-treated HIV-infected patients. J Clin Invest 2005; 115(7):1839-47; PMID: 15937547; https://doi.org/10.1172/JCI24307
   PubMed Web of Science ®Google Scholar
• Weiss L, Letimier FA, Carriere M, Maiella S, Donkova-Petrini V, Targat B, Benecke A, Rogge L, Levy Y. In vivo expansion of naive and activated CD4+CD25+FOXP3+ regulatory T cell populations in interleukin-2-treated HIV patients. Proc Natl Acad Sci U S A 2010; 107(23):10632-7; PMID: 20498045; https://doi.org/10.1073/pnas.1000027107
   PubMed Web of Science ®Google Scholar
• MacPherson PA, Fex C, Sanchez-Dardon J, Hawley-Foss N, Angel JB. Interleukin-7 receptor expression on CD8(+) T cells is reduced in HIV infection and partially restored with effective antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 28(5):454-7; PMID: 11744834; https://doi.org/10.1097/00042560-200112150-00008
   PubMed Web of Science ®Google Scholar
• Paiardini M, Cervasi B, Albrecht H, Muthukumar A, Dunham R, Gordon S, Radziewicz H, Piedimonte G, Magnani M, Montroni M, et al. Loss of CD127 expression defines an expansion of effector CD8+ T cells in HIV-infected individuals. J Immunol 2005; 174(5):2900-9; PMID: 15728501; https://doi.org/10.4049/jimmunol.174.5.2900
   PubMed Web of Science ®Google Scholar
• Mackall CL, Fry TJ, Gress RE. Harnessing the biology of IL-7 for therapeutic application. Nat Rev Immunol 2011; 11(5):330-42; PMID: 21508983; https://doi.org/10.1038/nri2970
   PubMed Web of Science ®Google Scholar
• Fry TJ, Mackall CL. Interleukin-7: master regulator of peripheral T-cell homeostasis? Trends Immunol 2001; 22(10):564-71; PMID: 11574281; https://doi.org/10.1016/S1471-4906(01)02028-2
   PubMed Web of Science ®Google Scholar
• Lévy Y, Sereti I, Tambussi G, Routy JP, Lelièvre JD, Delfraissy JF, Molina JM, Fischl M, Goujard C, Rodriguez B, et al. Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I/IIa randomized, placebo-controlled, multicenter study. Clin Infect Dis 2012; 55(2):291-300; PMID: 22550117; https://doi.org/10.1093/cid/cis383
   PubMed Web of Science ®Google Scholar
• Thiébaut R, Jarne A, Routy JP, Sereti I, Fischl M, Ive P, Speck RF, D'Offizi G, Casari S, Commenges D, et al. Repeated cycles of recombinant human interleukin 7 in HIV-infected patients with low CD4 T-cell reconstitution on antiretroviral therapy: results of 2 phase II multicenter studies. Clin Infect Dis 2016; 62(9):1178-85; PMID: 26908786; https://doi.org/10.1093/cid/ciw065
   PubMed Web of Science ®Google Scholar
• Katlama C, Lambert-Niclot S, Assoumou L, Papagno L, Lecardonnel F, Zoorob R, Tambussi G, Clotet B, Youle M, Achenbach CJ, et al. Treatment intensification followed by interleukin-7 reactivates HIV without reducing total HIV DNA: a randomized trial. AIDS 2016; 30(2):221-30; PMID: 26684819; https://doi.org/10.1097/QAD.0000000000000894
   PubMed Web of Science ®Google Scholar
• Mueller YM, Bojczuk PM, Halstead ES, Kim AH, Witek J, Altman JD, Katsikis PD. IL-15 enhances survival and function of HIV-specific CD8+ T cells. Blood 2003; 101(3):1024-9; PMID: 12393488; https://doi.org/10.1182/blood-2002-07-1957
   PubMed Web of Science ®Google Scholar
• Ramanathan MP, Kutzler MA, Kuo YC, Yan J, Liu H, Shah V, Bawa A, Selling B, Sardesai NY, Kim JJ, et al. Coimmunization with an optimized IL15 plasmid adjuvant enhances humoral immunity via stimulating B cells induced by genetically engineered DNA vaccines expressing consensus JEV and WNV E DIII. Vaccine 2009; 27(32):4370-80; PMID: 19497647; https://doi.org/10.1016/j.vaccine.2009.01.137
   PubMed Web of Science ®Google Scholar
• Micci L, Cervasi B, Ende ZS, Iriele RI, Reyes-Aviles E, Vinton C, Else J, Silvestri G, Ansari AA, Villinger F, et al. Paucity of IL-21-producing CD4(+) T cells is associated with Th17 cell depletion in SIV infection of rhesus macaques. Blood 2012; 120(19):3925-35; PMID: 22990011; https://doi.org/10.1182/blood-2012-04-420240
   PubMed Web of Science ®Google Scholar
• Pallikkuth S, Rogers K, Villinger F, Dosterii M, Vaccari M, Franchini G, Pahwa R, Pahwa S. Interleukin-21 administration to rhesus macaques chronically infected with simian immunodeficiency virus increases cytotoxic effector molecules in T cells and NK cells and enhances B cell function without increasing immune activation or viral replication. Vaccine 2011; 29(49):9229-38; PMID: 21996099; https://doi.org/10.1016/j.vaccine.2011.09.118
   PubMed Web of Science ®Google Scholar
• Micci L, Ryan ES, Fromentin R, Bosinger SE, Harper JL, He T, Paganini S, Easley KA, Chahroudi A, Benne C, et al. Interleukin-21 combined with ART reduces inflammation and viral reservoir in SIV-infected macaques. J Clin Invest 2015; 125(12):4497-513; PMID: 26551680; https://doi.org/10.1172/JCI81400
   PubMed Web of Science ®Google Scholar
• Hong Z, Jiang Z, Liangxi W, Guofu D, Ping L, Yongling L, Wendong P, Minghai W. Chloroquine protects mice from challenge with CpG ODN and LPS by decreasing proinflammatory cytokine release. Int Immunopharmacol 2004; 4(2):223-34; PMID: 14996414; https://doi.org/10.1016/j.intimp.2003.12.006
   PubMed Web of Science ®Google Scholar
• Wozniacka A, Lesiak A, Narbutt J, McCauliffe DP, Sysa-Jedrzejowska A. Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients. Lupus 2006; 15(5):268-75; PMID: 16761500; https://doi.org/10.1191/0961203306lu2299oa
   PubMed Web of Science ®Google Scholar
• Sperber K, Louie M, Kraus T, Proner J, Sapira E, Lin S, Stecher V, Mayer L. Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1. Clin Ther 1995; 17(4):622-36; PMID: 8565026; https://doi.org/10.1016/0149-2918(95)80039-5
   PubMed Web of Science ®Google Scholar
• Sperber K, Chiang G, Chen H, Ross W, Chusid E, Gonchar M, Chow R, Liriano O. Comparison of hydroxychloroquine with zidovudine in asymptomatic patientsi nfected with human immunodeficiency virus type 1. Clin Ther 1997; 19(5):913-23; PMID: 9385480; https://doi.org/10.1016/S0149-2918(97)80045-8
   PubMed Web of Science ®Google Scholar
• Murray SM, Down CM, Boulware DR, Stauffer WM, Cavert WP, Schacker TW, Brenchley JM, Douek DC. Reduction of immune activation with chloroquine therapy during chronic HIV infection. J Virol 2010; 84(22):12082-6; PMID: 20844049; https://doi.org/10.1128/JVI.01466-10
   PubMed Web of Science ®Google Scholar
• Piconi S, Parisotto S, Rizzardini G, Passerini S, Terzi R, Argenteri B, Meraviglia P, Capetti A, Biasin M, Trabattoni D, et al. Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders. Blood 2011; 118(12):3263-72; PMID: 21576701; https://doi.org/10.1182/blood-2011-01-329060
   PubMed Web of Science ®Google Scholar
• Paton NI, Goodall RL, Dunn DT, Franzen S, Collaco-Moraes Y, Gazzard BG, Williams IG, Fisher MJ, Winston A, Fox J, et al. Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial. JAMA 2012; 308(4):353-61; PMID: 22820788; https://doi.org/10.1001/jama.2012.6936
   PubMed Web of Science ®Google Scholar
• Routy JP, Angel JB, Patel M, Kanagaratham C, Radzioch D, Kema I, Gilmore N, Ancuta P, Singer J, Jenabian MA. Assessment of chloroquine as a modulator of immune activation to improve CD4 recovery in immune nonresponding HIV-infected patients receiving antiretroviral therapy. HIV Med 2015; 16(1):48-56; PMID: 24889179; https://doi.org/10.1111/hiv.12171
   PubMed Web of Science ®Google Scholar
• Jacobson JM, Bosinger SE, Kang M, Belaunzaran-Zamudio P, Matining RM, Wilson CC, Flexner C, Clagett B, Plants J, Read S, et al. The effect of chloroquine on immune activation and interferon signatures associated with HIV-1. AIDS Res Hum Retroviruses 2016; 32(7):636-47; PMID: 26935044; https://doi.org/10.1089/aid.2015.0336
   PubMed Web of Science ®Google Scholar
• Tabb B, Morcock DR, Trubey CM, Quiñones OA, Hao XP, Smedley J, Macallister R, Piatak M Jr, Harris LD, Paiardini M, et al. Reduced inflammation and lymphoid tissue immunopathology in rhesus macaques receiving anti-tumor necrosis factor treatment during primary simian immunodeficiency virus infection. J Infect Dis 2013; 207(6):880-92; PMID: 23087435; https://doi.org/10.1093/infdis/jis643
   PubMed Web of Science ®Google Scholar
• Hsu DC, Faldetta KF, Pei L, Sheikh V, Utay NS, Roby G, Rupert A, Fauci AS, Sereti I. A paradoxical treatment for a paradoxical condition: infliximab use in three cases of mycobacterial IRIS. Clin Infect Dis 2016; 62(2):258-61; PMID: 26394669; https://doi.org/10.1093/cid/civ841
   PubMed Web of Science ®Google Scholar
• Rizzardi GP, Harari A, Capiluppi B, Tambussi G, Ellefsen K, Ciuffreda D, Champagne P, Bart PA, Chave JP, Lazzarin A, et al. Treatment of primary HIV-1 infection with cyclosporin a coupled with highly active antiretroviral therapy. J Clin Invest 2002; 109(5):681-8; PMID: 11877476; https://doi.org/10.1172/JCI0214522
   PubMed Web of Science ®Google Scholar
• Lederman MM, Smeaton L, Smith KY, Rodriguez B, Pu M, Wang H, Sevin A, Tebas P, Sieg SF, Medvik K, et al. Cyclosporin A provides no sustained immunologic benefit to persons with chronic HIV-1 infection starting suppressive antiretroviral therapy: results of a randomized, controlled trial of the AIDS clinical trials group A5138. J Infect Dis 2006; 194(12):1677-85; PMID: 17109339; https://doi.org/10.1086/509261
   PubMed Web of Science ®Google Scholar
• Markowitz M, Vaida F, Hare CB, Boden D, Mohri H, Hecht FM, Kalayjian RC, Conrad A, Mildvan D, Aberg J, et al. The virologic and immunologic effects of cyclosporine as an adjunct to antiretroviral therapy in patients treated during acute and early HIV-1 infection. J Infect Dis 2010; 201(9):1298-302; PMID: 20235838; https://doi.org/10.1086/651664
   PubMed Web of Science ®Google Scholar
• Coull JJ, Turner D, Melby T, Betts MR, Lanier R, Margolis DM. A pilot study of the use of mycophenolate mofetil as a component of therapy for multidrug-resistant HIV-1 infection. J Acquir Immune Defic Syndr 2001; 26(5):423-34; PMID: 11391161; https://doi.org/10.1097/00126334-200104150-00004
   PubMed Web of Science ®Google Scholar
• Di Benedetto F, Di Sandro S, De Ruvo N, Montalti R, Ballarin R, Guerrini GP, Spaggiari M, Guaraldi G, Gerunda G. First report on a series of HIV patients undergoing rapamycin monotherapy after liver transplantation. Transplantation 2010; 89(6):733-8; PMID: 20048692; https://doi.org/10.1097/TP.0b013e3181c7dcc0
   PubMed Web of Science ®Google Scholar
• Trautmann L, Janbazian L, Chomont N, Said EA, Gimmig S, Bessette B, Boulassel MR, Delwart E, Sepulveda H, Balderas RS, et al. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med 2006; 12(10):1198-202; PMID: 16917489; https://doi.org/10.1038/nm1482
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Pantazis N, Martin GE, Hickling S, Hurst J, Meyerowitz J, Willberg CB, Robinson N, Brown H, Fisher M, et al. Exhaustion of activated CD8 T cells predicts disease progression in primary HIV-1 infection. PLoS Pathog 2016; 12(7):e1005661; PMID: 27415828; https://doi.org/10.1371/journal.ppat.1005661
   PubMed Web of Science ®Google Scholar
• Velu V, Shetty RD, Larsson M, Shankar EM. Role of PD-1 co-inhibitory pathway in HIV infection and potential therapeutic options. Retrovirology 2015; 12:14; PMID: 25756928; https://doi.org/10.1186/s12977-015-0144-x
   PubMed Web of Science ®Google Scholar